Patents by Inventor Donghui Shi
Donghui Shi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11965029Abstract: Described herein are compositions and methods related to antigen binding proteins that bind to human ST2, including antibodies. In particular embodiments, the disclosure provides fully human anti-ST2 antibodies and deriviatives and variants thereof. Further provided are nucleic acids encoding such antibodies and antibody fragments, variants, and derivatives. Also, provided are methods of making and using such antibodies including methods of treating and preventing autoimmune and inflammatory disorders.Type: GrantFiled: June 4, 2021Date of Patent: April 23, 2024Assignee: Amgen Inc.Inventors: Dirk E. Smith, Ian Foltz, Chadwick T. King, Ai Ching Lim, Rutilio Clark, Michael R. Comeau, Randal R. Ketchem, Donghui Shi, Xiaoshan Min, Zhulun Wang
-
Publication number: 20220119537Abstract: Described herein are compositions and methods related to antigen binding proteins that bind to human ST2, including antibodies. In particular embodiments, the disclosure provides fully human anti-ST2 antibodies and deriviatives and variants thereof. Further provided are nucleic acids encoding such antibodies and antibody fragments, variants, and derivatives. Also, provided are methods of making and using such antibodies including methods of treating and preventing autoimmune and inflammatory disorders.Type: ApplicationFiled: June 4, 2021Publication date: April 21, 2022Applicant: Amgen Inc.Inventors: Dirk E. SMITH, Ian FOLTZ, Chadwick T. KING, Ai Ching LIM, Rutilio CLARK, Michael R. COMEAU, Randal R. KETCHEM, Donghui SHI, Xiaoshan MIN, Zhulun WANG
-
Publication number: 20220025059Abstract: Methods of treating metabolic diseases and disorders using an antigen binding protein specific for the GIPR polypeptide are provided. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy. In certain embodiments the antigen binding protein is administered in combination with a GLP-1 receptor agonist.Type: ApplicationFiled: May 27, 2021Publication date: January 27, 2022Applicant: AMGEN INC.Inventors: Junming YIE, Donghui SHI, David J. LLOYD, Jinghong WANG, Glenn N. SIVITS, JR., Murielle M. VENIANT-ELLISON, Renee KOMOROWSKI, Neeraj AGRAWAL, Darren L. BATES, Brandon C. P. CLAVETTE, Ian N. FOLTZ, Shu-yin HO, Christopher MURAWSKY, Xiaoshan MIN, Zhulun WANG
-
Patent number: 11059895Abstract: Described herein are compositions and methods related to antigen binding proteins that bind to human ST2, including antibodies. In particular embodiments, the disclosure provides fully human anti-ST2 antibodies and derivatives and variants thereof. Further provided are nucleic acids encoding such antibodies and antibody fragments, variants, and derivatives. Also, provided are methods of making and using such antibodies including methods of treating and preventing autoimmune and inflammatory disorders.Type: GrantFiled: January 8, 2019Date of Patent: July 13, 2021Assignee: Amgen Inc.Inventors: Dirk E. Smith, Ian Foltz, Chadwick T. King, Ai Ching Lim, Rutilio Clark, Michael R. Comeau, Randal R. Ketchem, Donghui Shi, Xiaoshan Min, Zhulun Wang
-
Patent number: 11046774Abstract: Methods of treating metabolic diseases and disorders using an antigen binding protein specific for the GIPR polypeptide are provided. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy. In certain embodiments the antigen binding protein is administered in combination with a GLP-1 receptor agonist.Type: GrantFiled: February 25, 2019Date of Patent: June 29, 2021Assignee: AMGEN INC.Inventors: Junming Yie, Donghui Shi, David J. Lloyd, Jinghong Wang, Glenn N. Sivits, Jr., Murielle M. Veniant-Ellison, Renee Komorowski, Neeraj Agrawal, Darren L. Bates, Brandon C. P. Clavette, Ian N. Foltz, Shu-yin Ho, Christopher Murawsky, Xiaoshan Min, Zhulun Wang
-
Publication number: 20210087286Abstract: Methods of treating metabolic diseases and disorders using an antigen binding protein specific for the GIPR polypeptide are provided. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy. In certain embodiments the antigen binding protein is administered in combination with a GLP-1 receptor agonist.Type: ApplicationFiled: June 20, 2018Publication date: March 25, 2021Applicant: AMGEN INC.Inventors: Darren L. BATES, Donghui SHI, David J. LLOYD, Pavel BONDARENKO, Mark L. MICHAELS, Todd HAGER, Xiaoshan MIN, Aiko UMEDA, Irwin CHEN, Zhulun WANG
-
Publication number: 20190359720Abstract: Described herein are compositions and methods related to antigen binding proteins that bind to human ST2, including antibodies. In particular embodiments, the disclosure provides fully human anti-ST2 antibodies and derivatives and variants thereof. Further provided are nucleic acids encoding such antibodies and antibody fragments, variants, and derivatives. Also, provided are methods of making and using such antibodies including methods of treating and preventing autoimmune and inflammatory disorders.Type: ApplicationFiled: January 8, 2019Publication date: November 28, 2019Applicant: Amgen Inc.Inventors: Dirk E. SMITH, Ian FOLTZ, Chadwick T. KING, Ai Ching LIM, Rutilio CLARK, Michael R. COMEAU, Randal R. KETCHEM, Donghui SHI, Xiaoshan MIN, Zhulun WANG
-
Publication number: 20190276546Abstract: Methods of treating metabolic diseases and disorders using an antigen binding protein specific for the GIPR polypeptide are provided. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy. In certain embodiments the antigen binding protein is administered in combination with a GLP-1 receptor agonist.Type: ApplicationFiled: February 25, 2019Publication date: September 12, 2019Applicant: AMGEN INC.Inventors: Junming Yie, Donghui Shi, David J. Lloyd, Jinghong Wang, Glenn N. Sivits, JR., Murielle M. Veniant-Ellison, Renee Komorowski, Neeraj Agrawal, Darren L. Bates, Brandon C. P. Clavette, Ian N. Foltz, Shu-yin Ho, Christopher Murawsky, Xiaoshan Min, Zhulun Wang
-
Patent number: 10294303Abstract: Methods of treating metabolic diseases and disorders using an antigen binding protein specific for the GIPR polypeptide are provided. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy. In certain embodiments the antigen binding protein is administered in combination with a GLP-1 receptor agonist.Type: GrantFiled: December 21, 2016Date of Patent: May 21, 2019Assignee: AMGEN INC.Inventors: Junming Yie, Donghui Shi, David J. Lloyd, Jinghong Wang, Glenn N. Sivits, Jr., Murielle M. Veniant-Ellison, Renee Komorowski, Neeraj Agrawal, Darren L. Bates, Brandon C. P. Clavette, Ian N. Foltz, Shu-yin Ho, Christopher Murawsky, Xiaoshan Min, Zhulun Wang
-
Patent number: 10227414Abstract: Described herein are compositions and methods related to antigen binding proteins that bind to human ST2, including antibodies. In particular embodiments, the disclosure provides fully human anti-ST2 antibodies and deriviatives and variants thereof. Further provided are nucleic acids encoding such antibodies and antibody fragments, variants, and derivatives. Also, provided are methods of making and using such antibodies including methods of treating and preventing autoimmune and inflammatory disorders.Type: GrantFiled: May 22, 2017Date of Patent: March 12, 2019Assignee: Amgen Inc.Inventors: Dirk E. Smith, Ian Foltz, Chadwick T. King, Ai Ching Lim, Rutilio Clark, Michael R. Comeau, Randal R. Ketchem, Donghui Shi, Xiaoshan Min, Zhulun Wang
-
Patent number: 9982054Abstract: Described herein are compositions and methods related to antigen binding proteins that bind to human ST2, including antibodies. In particular embodiments, the disclosure provides fully human anti-ST2 antibodies and deriviatives and variants thereof. Further provided are nucleic acids encoding such antibodies and antibody fragments, variants, and derivatives. Also, provided are methods of making and using such antibodies including methods of treating and preventing autoimmune and inflammatory disorders.Type: GrantFiled: June 10, 2016Date of Patent: May 29, 2018Assignee: AMGEN INC.Inventors: Dirk E. Smith, Ian Foltz, Chadwick T. King, Ai Ching Lim, Rutilio Clark, Michael R. Comeau, Randal R. Ketchem, Donghui Shi, Xiaoshan Min, Zhulun Wang
-
Publication number: 20170275370Abstract: Methods of treating metabolic diseases and disorders using an antigen binding protein specific for the GIPR polypeptide are provided. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy. In certain embodiments the antigen binding protein is administered in combination with a GLP-1 receptor agonist.Type: ApplicationFiled: December 21, 2016Publication date: September 28, 2017Applicant: AMGEN INC.Inventors: Junming YIE, Donghui SHI, David J. LLOYD, Jinghong WANG, Glenn N. SIVITS, JR., Murielle M. VENIANT-ELLISON, Renee KOMOROWSKI, Neeraj AGRAWAL, Darren L. BATES, Brandon C. P. CLAVETTE, Ian N. FOLTZ, Shu-yin HO, Christopher MURAWSKY, Xiaoshan MIN, Zhulun WANG
-
Publication number: 20170267769Abstract: Described herein are compositions and methods related to antigen binding proteins that bind to human ST2, including antibodies. In particular embodiments, the disclosure provides fully human anti-ST2 antibodies and deriviatives and variants thereof. Further provided are nucleic acids encoding such antibodies and antibody fragments, variants, and derivatives. Also, provided are methods of making and using such antibodies including methods of treating and preventing autoimmune and inflammatory disorders.Type: ApplicationFiled: May 22, 2017Publication date: September 21, 2017Applicant: Amgen Inc.Inventors: Dirk E. SMITH, Ian FOLTZ, Chadwick T. KING, Ai Ching LIM, Rutilio CLARK, Michael R. COMEAU, Randal R. KETCHEM, Donghui SHI, Xiaoshan MIN, Zhulun WANG
-
Publication number: 20170002079Abstract: Described herein are compositions and methods related to antigen binding proteins that bind to human ST2, including antibodies. In particular embodiments, the disclosure provides fully human anti-ST2 antibodies and deriviatives and variants thereof. Further provided are nucleic acids encoding such antibodies and antibody fragments, variants, and derivatives. Also, provided are methods of making and using such antibodies including methods of treating and preventing autoimmune and inflammatory disorders.Type: ApplicationFiled: June 10, 2016Publication date: January 5, 2017Applicant: Amgen Inc.Inventors: Dirk E. SMITH, Ian FOLTZ, Chadwick T. KING, Ai Ching LIM, Rutilio CLARK, Michael R. COMEAU, Randal R. KETCHEM, Donghui SHI, Xiaoshan MIN, Zhulun WANG
-
Patent number: 9382318Abstract: Described herein are compositions and methods related to antigen binding proteins that bind to human ST2, including antibodies. In particular embodiments, the disclosure provides fully human anti-ST2 antibodies and deriviatives and variants thereof. Further provided are nucleic acids encoding such antibodies and antibody fragments, variants, and derivatives. Also, provided are methods of making and using such antibodies including methods of treating and preventing autoimmune and inflammatory disorders.Type: GrantFiled: May 17, 2013Date of Patent: July 5, 2016Assignee: Amgen Inc.Inventors: Dirk E. Smith, Ian Foltz, Chadwick T. King, Ai Ching Lim, Rutilio Clark, Michael R. Comeau, Randal R. Ketchem, Donghui Shi, Xiaoshan Min, Zhulun Wang